Natco Pharma completes 35.75% stake buy in South Africa's Adcock Ingram

Listed-company acquisitionOpen offer triggeredStrategic Transactions View source PDF Explain this filing

NATCOPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.9%Reaction day

₹793.00

prior close

₹825.60

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.7%+3.2% vs market

Pharmaceuticals peers, median of 157sector+0.8%+3.1% vs sector

On the reaction day the stock moved 3.2 pts more than Nifty Smallcap 250 and 3.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

-0.6

15m

-0.3

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.9+0.7+3.2+0.8+3.1

Next day

+4.1+0.3+3.8+0.5+3.7

+2.4+0.5+1.9+0.4+2.1

+3.4+1.2+2.2+0.4+3.0

+2.6+0.2+2.5-0.1+2.8

+4.7-0.3+4.9-0.6+5.3

+8.7-1.6+10.3-1.2+9.9

15d

+17.7-2.2+19.9-1.8+19.6

+14.1-3.5+17.6-2.6+16.7

+8.6-5.3+13.8-5.4+14.0

+5.4-4.4+9.7-6.0+11.3

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Natco Pharma has completed acquiring a 35.75 percent stake in South African pharmaceutical major Adcock Ingram, valued at about US dollar 226 million (around ZAR 4 billion). Adcock Ingram, founded in 1891, has delisted from the Johannesburg Stock Exchange on November 11, 2025. The deal was approved by shareholders in October 2025 at an offer price of ZAR 75 per share. Adcock holds about 10 percent market share in South Africa's private pharma market and leads the OTC segment.

Likely market impact

Strategic entry into South African pharma market, expanding Natco's global footprint. Positive long-term growth signal as deal is already completed and funded.